Clinical Trials Directory

Trials / Sponsors / Galecto Biotech AB

Galecto Biotech AB

Industry · 9 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingAn Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute M
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1 / Phase 22026-06-10
CompletedA Study to Compare Pharmacokinetics of GB1211
Pharmacokinetics
Phase 12023-01-03
Active Not RecruitingA Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezoliz
Non-Small Cell Lung Cancer
Phase 1 / Phase 22022-03-15
UnknownA Single and Repeat Dose Trial in Participants With Hepatic Impairment
Hepatic Impairment
Phase 1 / Phase 22021-09-09
Active Not RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Particip
Myelofibrosis
Phase 22021-06-09
WithdrawnA Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1
Non-alcoholic Steatohepatitis (NASH)
Phase 1 / Phase 22021-03-01
CompletedA Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)
Phase 22019-02-19
CompletedA First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
Safety and Tolerability
Phase 12019-01-14
CompletedRCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
Idiopathic Pulmonary Fibrosis
Phase 1 / Phase 22014-09-01